Treatment Outcome of Jaundice and Its Associated Factors Among Neonates Treated in Neonatal Intensive Care Unit of Comprehensive and Specialized Hospitals of Southern Nations Nationalities and Peoples Region, Ethiopia 2022

• Published in: Pediatric health, medicine and therapeutics Vol. 14; pp. 237 - 247
• Main Authors: Kebede, Christian, Fentie, Beletech, Tigabu, Bethelihem
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 31.07.2023; Dove; Dove Medical Press
• Subjects: Analysis; Bilirubin; hyperbilirubinemia; Infants (Premature); Jaundice; Neonatal intensive care; neonate; Neonatology; Original Research; Patient outcomes; treatment outcome; Nigeria; Nepal; Ethiopia; India; jaundice; neonate; treatment outcome; hyperbilirubinemia
• ISSN: 1179-9927; 1179-9927
• DOI: 10.2147/PHMT.S405453

Jaundice is a common problem that affects up to 50-60% of full-term babies and 80% of preterm babies. It is a benign condition, but sometimes it can cause profound complications and eventually death. Identifying the treatment outcome of jaundice and the factors affecting it is crucial to preventing the death associated with it. To determine the treatment outcome of jaundice and its associated factors among neonates treated in neonatal intensive care unit of comprehensive and specialized hospitals of SNNPR, Ethiopia, 2022. An institution-based retrospective follow up study was conducted from April 2018 to April 2022. The data was checked for completeness and then entered into Epi-data version 4.6 and exported to STATA version 17. The results were presented in frequencies and percentages for categorical variables as well as mean and median for continuous variables. A binary logistic regression model was used to estimate the effect of an independent variable and the outcome variable. A total of 423 charts were reviewed, and 416 (98%) were included in the final analysis. Almost 91.3% (95% CI: 88.2, 93.7) of neonates had improved. Factors significantly associated with the treatment outcome were: residence (AOR = 0.36, 95% CI: 0.2, 0.8); origin of admission (AOR = 0.35, 95% CI: 0.2, 0.8); gestational age (AOR = 0.26, 95% CI: 0.1, 0.8); and total serum bilirubin level (AOR = 0.40, 95% CI: 0.2, 0.9). Improvement was lower compared to other low and middle-income countries; more emphasis should be given to improving treatment outcomes in hospitals.